Cellular mechanisms of tumor rejection in rats.
The mechanisms of tumor rejection by cell-mediated immunity were reviewed in a rat autochthonous and syngeneic tumor-host system. The immune system could mediate a complete regression of autochthonous tumor if the tumor cells were immunogenic. Neutrophils and macrophages first appeared following transplantation of autochthonous tumor. Lymphocytes increased in the tumor tissue as the tumor began to show regression. Degenerated tumor tissue was infiltrated by macrophages and plasma cells. The identification of rat hematopoietic cells including various subsets of lymphocytes and inflammatory cells became possible owing to a variety of monoclonal antibodies reacting with these cells. Major populations of tumor-infiltrating lymphocytes (TIL) were found to be R1-3B3 (CD5)- and R1-10B5 (CD8)-positive cells in methylcholanthrene-induced autochthonous tumor. These CD5- and CD8-positive lymphocytes were also recognized in an N-nitrosourea-induced syngeneic tumor-host system and actually showed specific cytotoxicity against tumor cells in vitro. Macrophages were recognized in tumor tissues more predominantly in the early and terminal phase of tumor rejection; their functions are still uncertain but they are considered to have important immunomodulatory effects. A variety of cytokines were thought to play an important role in augmenting host immunity to achieve tumor rejection. Neutrophils in the tumor tissue were shown to produce a factor attracting lymphocytes to the tumor site, which was designated as lymphocyte migration factor. Subsequently, activities of colony-stimulating factor, interleukin-1, -2, and -3, and cytotoxic-T-cell-generating factor (CGF), which induces final maturation of cytotoxic T cells, were detected at the tumor site as well as in the regional lymph nodes and the spleen. CGF was found to be produced by W3/25 (CD4)-positive T cells. Lymphocytes residing in the spleen of the immune rats did not show cytotoxic activity against tumor cells but significant tumor lysis activity was recognized with TIL. This suggests that lymphocytes may achieve maturation after they leave the spleen. Cellular reactions occurring at the tumor site were enhanced at each step by various cytokines produced by lymphocytes as well as by inflammatory cells. This cytokine cascade seems to be essential for obtaining a sufficient immune response for tumor rejection. When an established T9 subcutaneous tumor with a diameter of 10 mm was treated by intratumoral infusion of lymphokine-activated killer (LAK) cells, the tumor showed complete regression after 2-3 weeks of transient growing.(ABSTRACT TRUNCATED AT 400 WORDS)
Department of Neurosurgery, Sapporo Medical College, Japan.
T
T
Yamaki
T
T
Uede
K
K
Kikuchi
D000818:Animals; D007111:Immunity, Cellular; D007167:Immunotherapy; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology; D009374:Neoplasms, Experimental / Q000235:genetics / Q000276:immunology* / Q000628:therapy; D051381:Rats; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology